A United States-based biotechnology company is seeking to employ up to 100 Filipino developers and engineers to handle the information technology (IT) segment of its operations.
The new office of Filipino-owned InterVenn Biosciences is located at the Podium West Tower in Ortigas central business district in Mandaluyong City. It is set to open on January 15, 2022.
“The new site will expand the local team’s roster of developers and engineers that form the backbone running the proprietary artificial-intelligence (AI) technology used in the company’s research,” the company said in a recent statement.
The company is headquartered in San Francisco, California but the AI technology team is mostly comprised of Filipinos residing locally.
“One hundred percent of our software is done in the Philippines,” InterVenn Founder and CEO Aldo Carrascoso said. “Our engineering team in our Mandaluyong City office takes care of the cloud infrastructure, front end, back end, and even security. Information security, information event management, events like infiltration, penetration testing. We have a full staff that does dev ops, server systems administration.”
The biotech firm recently obtained a P10-billion from Series C financing led by SoftBank Group. The funding is earmarked for company’s growth and investments in healthcare industry.
The capital infusion also supports the development and commercialization of Dawn, which is a blood-based test aimed at aiding physicians in matching cancer patients with the best possible immuno-oncology therapy.
The cancer technology is currently in an early validation process for use in patients with pancreatic and lung cancers and melanoma. The company is also studying its application on other types of tumor.
InterVenn is a pioneering medical company in glycoproteomic research and development. It employs a proprietary platform powered by AI and mass spectrometry to help advance oncology and other related fields.
Image courtesy of Contributed Photo
Read full article on BusinessMirror
